In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EU animal testing

This article was originally published in The Rose Sheet

Executive Summary

Seventh Amendment to Cosmetics Directive including animal testing ban is under review by Council of Ministers technical working group, but may not be mature enough to reach full Council by June meeting, in which case it will be reviewed in September, EU says. Parliament-approved draft including marketing ban on cosmetics tested on animals in addition to testing ban has led to dissent among working group, EU says. If amendment review is delayed, deliberation will continue under Belgian Presidency rather than Swedish Presidency, which has been championing ban. Even if marketing ban does not pass Council, Parliament could reinstate it upon second reading. Parliament passed Seventh Amendment in April after environmental committee recommended marketing ban in March (1"The Rose Sheet" April 9, p. 12 and 2March 26, pp. 3-5)

Latest Headlines
See All
UsernamePublicRestriction

Register

RS009242

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel